Nasdaq apls.

WALTHAM, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...Apr 24, 2023 · The forecasts range from a low of 51.51 to a high of $148.05. The average price target represents a decrease of 4.25% from its latest reported closing price of 93.18. See our leaderboard of ... Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...Cash and cash equivalents of $765 million as of March 31, 2023; expected cash runway into Q1 2025. WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its first quarter 2023 financial results and business highlights.

We challenge conventional thinking and always question if there's a better way. Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology ...GA is an advanced form of age-related macular degeneration and a leading cause of blindness that impacts approximately one million AmericansWinkler and his family saw firsthand the impact of vision... -April 17, 2023 at 07:01 am- MarketScreener

WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...

Operating as a commercial-stage biopharmaceutical entity, Apellis Pharmaceuticals (NASDAQ:APLS) is dedicated to the discovery, development, and market introduction of groundbreaking therapeutic ...25 сент. 2023 г. ... Apellis Pharmaceuticals (NASDAQ:APLS) announced Monday that the U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent ...Stock analysis for Apellis Pharmaceuticals Inc (APLS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company ...Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2023 Free Trial Top-Rated Stocks Most-Upgraded Stocks Apellis Pharmaceuticals (APLS) Stock …Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and

Bill Oxford/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Beam Therapeutics (NASDAQ:BEAM) will collaborate to develop therapies for complement-driven diseases.; The body's ...

6 de nov. de 2023 ... 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity ...

Nov 30, 2023 · APLS is trading at a 30% discount. Price $53.92. Nov 30, 2023. Fair Value $86.12. Nov 30, 2023 ... Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Get 7 Days Free Sign In Sign In Topics6 de nov. de 2023 ... 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity ...WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Contact Us U.S. markets close in 1 hour 31 minutes Apellis Pharmaceuticals, Inc. (APLS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 60.83 …

CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel ...WALTHAM, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022 at 4:30 p.m. ET. To access …WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced ...(NASDAQ: APLS) Apellis Pharmaceuticals currently has 118,499,945 outstanding shares. With Apellis Pharmaceuticals stock trading at $61.58 per share, the total ...

Apellis Pharmaceuticals ( NASDAQ: APLS) can't seem to shake off safety concerns with its vision loss drug Syfovre (pegcetacoplan) and is down another ~6% on Tuesday. Adding to the company's woes ...

NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc. An investigation on behalf of current long term investors in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares over possible breaches of fiduciary duty by certain officers and directors was announced.31 de jul. de 2023 ... On today's stock market, APLS stock plummeted 19.6% to close at 25.75. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade ...WALTHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that two ...View today's Apellis Pharmaceuticals Inc stock price and latest APLS news and analysis. Create real-time notifications to follow any changes in the live ...Real time Apellis Pharmaceuticals (APLS) stock price quote, stock graph, news & analysis.1. Ramish Cheema. August 3, 2023 at 9:46 PM · 8 min read. In this piece, we will take a look at ten oversold midcap stocks to buy. If you want to skip an introduction to technical trading and the ...Apellis Pharmaceuticals Insider Sold Shares Worth $444,620, According to a Recent SEC Filing. Nov. 21. MT. Mizuho Raises Price Target on Apellis Pharmaceuticals to $49 …Apellis Pharmaceuticals last released its quarterly earnings data on November 1st, 2023. The reported ($1.17) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to the consensus estimate of $99.05 million. Its revenue was up 400.5% on a year-over-year basis.Find the latest dividend history for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.(NASDAQ: APLS) Apellis Pharmaceuticals currently has 118,499,945 outstanding shares. With Apellis Pharmaceuticals stock trading at $61.58 per share, the total ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...

Nov 17, 2023 · Apellis Pharmaceuticals Inc (NASDAQ:APLS) showed a performance of 4.00% in past 30-days. Number of shares sold short was 16.23 million shares which calculate 7.13 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $71.19 to the stock, which implies a rise of 32.73% to its current value. On today's stock market, APLS stock plummeted 37.9% to 52.46. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.WALTHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...APLS GAP FILL APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. Underlying @ entry 33.33 I'm a beginner so this is not advice. APLS just had a sell of due to bad results on trial. $20 gap formed on 9.10 & I've just entered a position for an eventual gap fill. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...WALTHAM, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the U.S ...Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ... Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue? Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. …WALTHAM, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.

Apellis Pharmaceuticals ( NASDAQ: APLS) can't seem to shake off safety concerns with its vision loss drug Syfovre (pegcetacoplan) and is down another ~6% on Tuesday. Adding to the company's woes ...Stock Quote & Chart. NASDAQ: APLS. $61.58. Dec 1, 2023 4:00 PM EST. Change. +7.71 (+14.31%). Volume. 5,431,264. Today's Open. $53.99. Previous Close. $53.87.WALTHAM, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will ...Instagram:https://instagram. forex demo account metatrader 4webull margin calculatorpgande stocksrealty income dividends Find the latest analyst research for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.Apellis Pharmaceuticals (NASDAQ: APLS) 2% HIGHER; BofA Securities upgraded the stock from Neutral to Buy with a price target of $85.00 (from $52.00). After-hours movers: GitLab surges on earnings ... tiktok payrollmcd payment Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.WALTHAM, Mass. and CRESTWOOD, Ky., June 06, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel ... best cash out refi lenders Get the latest Apellis Pharmaceuticals Inc (APLS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Nov 4, 2023 · WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 3 years of continuous treatment with ...